迪瑞醫療(300396.SZ)獲得2項醫療器械註冊證
格隆匯8月23日丨迪瑞醫療(300396.SZ)公佈，公司於近日取得由吉林省藥品監督管理局頒發的2項《醫療器械註冊證》。
1.產品名稱全自動尿液分析系統；臨牀用途：用於對人體尿液中理化指標以及尿液中有形成分進行定性、定量分析。
2.產品名稱全自動糖化血紅蛋白分析儀；臨牀用途：用於人體全血樣本或溶血樣本中糖化血紅蛋白的定量分析。
目前尿液分析技術在國內外已經成為臨牀檢驗項目的常規檢測技術，隨着國內廠商技術不斷進步，與國外尿液分析產品的差距不斷縮小，在二級及基層醫院市場逐漸完成了進口產品替代，並不斷搶佔進口尿液分析產品的市場份額。公司在尿液分析領域多年來積累了較強的產品、品牌優勢和技術儲備，新註冊的FUS-1000Plus型號全自動尿液分析系統，具有體積小巧、操作便捷等特性，一次進樣即可完成尿液幹化學及有形成分檢測，並具備多種測試模式可供選擇，可較好的滿足檢驗科及實驗室檢測需求。
糖尿病是全世界最主要的慢性非傳染性疾病之一，我國是糖尿病患病率增長最快的國家之一。糖化血紅蛋白是糖尿病患者判斷疾病控制程度的一項良好指標，可反映2-3個月的階段性血糖水平。糖化血紅蛋白作為糖尿病篩選、診斷、血糖控制、療效考核的有效檢測指標，在臨牀中得到了廣泛的使用。近年來，國內廠商在糖化血紅蛋白檢測系統領域不斷突破。公司此次新註冊的AH-100全自動糖化血紅蛋白分析儀，在臨牀樣本檢測中具有針對性強、自動化程度高、體積小、操作便捷等特性，可提供糖化血紅蛋白的動態檢測，為疾病篩查、預防及治療方案調整等方面提供重要依據。
上述《醫療器械註冊證》的取得，豐富和延續了公司產品種類，將進一步增強公司產品的綜合競爭力，有利於進一步提高公司的市場拓展能力，對公司未來的經營將產生積極影響。上述產品實際銷售情況取決於未來市場推廣效果，公司目前尚無法預測其對公司未來業績的影響，敬請投資者注意投資風險。公司未來會積極推動相關產品在國內市場的銷售，為廣大股東創造更大的價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
